Skip to main content

H20 Summit: The role of science, technology, and innovation and the future of PDPs coming out of this pandemic in supporting underserved populations

Wed, 1-9-2021 - Thu, 2-9-2021

A Call to Action to G20 Leaders, Health and Finance Ministers

The annual Health20 Summit on 1-2 September 2021, hosted by The G20 Health and Development Partnership, will be held virtually this year inviting G20 policymakers, international organisations, the global health community, economists, civil society and academia to join discussions and make concrete recommendations to G20 Health Ministers ahead of their summit about the future of global health crisis management and financing.

Panel 2: The role of Science, Technology, and Innovation and the future of PDPs coming out of this pandemic in supporting underserved populations

Since the 1990s, product development partnerships (PDPs) have played a crucial role in developing and facilitating access to new health technologies aimed at meeting the needs of underserved populations. These include people suffering from poverty-related diseases, such as AIDS, tuberculosis, malaria, and neglected tropical diseases, where a lack of market incentives has stalled innovation and progress in disease control and elimination.

The PDP model has proven equally crucial in the global response to COVID-19. During the COVID-19 crisis, PDPs have been playing a critical role by providing assets and expertise to the World Health Organization, the ACT Accelerator and other research coalitions. PDPs have also mitigated the impact of COVID-19 on poverty-related and neglected tropical diseases (PRNTDs) by successfully ensuring that product development, manufacturing and access to critical health tools continue without interruption, thus safeguarding the lifesaving impact of these activities.

This session will discuss how PDPs have helped deliver on the G20 global health goals, which funding models have so far successfully been put in place, and how the impact of collaborative research and product development can be further spearheaded and amplified for global health security and poverty reduction.


Jamie Nishi, Director, Global Health Technologies Coalition


David Reddy, CEO Medicines for Malaria Venture (MMV); Member of the Board, Coalition for Epidemic Preparedness Innovations (CEPI)


Bernard Pécoul, CEO of the Drugs for Neglected Diseases initiative (DNDi)

Bill Rodriguez, CEO of the Foundation for Innovative New Diagnostics (FIND)

Michael Strange, Head of Global Health Catalyst for Global Health R&D, GlaxoSmithKline (GSK)

Hiroki Nakatani, Chair and Representative Director, Global Health Innovative Technology Fund (GHIT)

Robin Davies, Head of the Indo-Pacific Centre for Health Security, Department of Foreign Affairs and Trade, Australia

Hayat Sindi, Senior Advisor to the President, Islamic Development Bank (IsDB)


Ana Maria Harkins, Director of External Affairs, TB Alliance